Showing 3661-3670 of 5693 results for "".
- Bausch + Lomb Launches enVista Aspire Monofocal and Toric IOLs in the European Unionhttps://modernod.com/news/bausch-lomb-launches-envista-aspire-monofocal-and-toric-iols-in-the-european-union/2482610/Bausch + Lomb announced the commercial launch of the enVista Aspire monofocal and toric IOLs in the European Union after receiving a CE Mark late last year. According to B+L, enVista Aspire combines 'intermediate optimized' optics, which are designed for a broader dept
- Alkeus Announces Interim TEASE-3 Study Results Evaluating Gildeuretinol in Early-Stage Stargardt Patientshttps://modernod.com/news/alkeus-announces-new-interim-tease-3-study-results-showing-gildeuretinol-prevented-disease-progression-in-early-stage-stargardt-patients/2482608/Alkeus Pharmaceuticals announced positive interim data from its TEASE-3 study demonstrating that additional early-stage Stargardt disease patients treated with oral gildeuretinol acetate showed no disease progression, including stable visual acuity, over multiple years. “Thes
- Altris AI Introduces AI-Powered Fluid and GA Quantification Featureshttps://modernod.com/news/altris-ai-introduces-ai-powered-fluid-and-ga-quantification-features/2482606/Altris AI, which utilizes artificial intelligence for OCT scan analysis, has unveiled additional quantification features for fluids and geographic atrophy (GA) tracking on its web platform. Altris AI currently detects more than 70 retina pathologies and biomarkers. The platform'
- Canyon Labs Acquire's iuvo BioScience’s Lab Services and Consulting Businesseshttps://modernod.com/news/canyon-labs-acquires-iuvo-biosciences-lab-services-and-consulting-businesses/2482600/Canyon Labs, a provider of analytical & packaging lab testing and consulting for medical devices and pharmaceuticals, has acquired the laboratory services and scientific consulting divisions of iuvo BioScience, a provider of ophthalmic medical device and pharmaceutical cli
- Topcon Healthcare Appoints Christian Odaker as Chief Technology Officerhttps://modernod.com/news/topcon-healthcare-appoints-christian-odaker-as-chief-technology-officer/2482599/Topcon Healthcare announced the appointment of Christian Odaker, PhD, to the role of Chief Technology Officer (CTO). Dr. Odaker willsupport the company's 'Healthcare from the Eye' initiative, which leverages AI-powered disease detection and management using da
- Regeneron Acquires UK-Based Biotech Oxularhttps://modernod.com/news/regeneron-acquires-uk-based-biotech-oxular/2482596/Regeneron has acquired Oxular, a clinical stage company making ocular delivery technology for retinal disorders. The news of the aquisition was made from a LinkedIn
- Prevent Blindness Provides Free Glaucoma Resources to Patients, Care Partners, and Professionalshttps://modernod.com/news/prevent-blindness-provides-free-glaucoma-resources-to-patients-care-partners-and-professionals/2482593/As part of January’s National Glaucoma Awareness Month, the non-profit Prevent Blindness is offering free educational resources to patients, care partners, and professionals. The resources include downloadable
- Opus Genetics Receives FDA Agreement Under SPA for Phase 3 Trial of APX3330 in DRhttps://modernod.com/news/opus-genetics-receives-fda-agreement-under-spa-for-phase-3-trial-of-apx3330-in-diabetic-retinopathy/2482587/Opus Genetics announced it has reached agreement with the FDA on a Special Protocol Assessment (SPA) for a phase 3 clinical trial evaluating oral APX3330 for the treatment of moderate to severe non-proliferative diabetic retinopathy (NPDR).
- Vabysmo Prefilled Syringe (PFS) Approved in the EUhttps://modernod.com/news/vabysmo-prefilled-syringe-pfs-approved-in-the-eu-for-three-retinal-conditions/2482582/The European Medicines Agency (EMA) has approved Roche's Vabysmo (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion
- Viridian Announces Topline Results from Veligrotug Phase 3 Trial in Patients with Chronic TEDhttps://modernod.com/news/viridian-announces-positive-topline-results-from-veligrotug-phase-3-trial-in-patients-with-chronic-thyroid-eye-disease/2482580/Viridian Therapeutics announced positive topline data from the THRIVE-2 phase 3 clinical trial of veligrotug (veli), an intravenously (IV) delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic thyroid eye disease (TED). “We are extremely